The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myeloid, Acute
  • Polypharmacy

abstract

  • We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4182134

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2014.06.018

PubMed ID

  • 25127690

Additional Document Info

start page

  • 1184

end page

  • 90

volume

  • 38

number

  • 10